Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nasal spray test could make allergy shots smarter and cheaper

NCT ID NCT04544774

Knowledge-focused Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a nasal allergen provocation test (NAPT) can help doctors start and monitor allergy immunotherapy more effectively. Researchers will follow 200 adults with allergic rhinitis who are beginning immunotherapy, using the NAPT along with blood tests and symptom questionnaires over three years. The goal is to see if this approach can improve treatment outcomes and reduce costs by tailoring therapy to each person's specific allergies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Allergen immunotherapy (AIT) – allergy shots or drops
What this could lead to
If successful, this could help doctors personalize allergy treatment, saving time and money by only treating the allergens that matter most.
What could go wrong
This is an observational study, not a test of a new treatment. It may not lead to changes in practice, and results depend on patient participation over three years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2020

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with persistent and intermittent allergic rhinitis who start with AIT treatment.

Ages

18 to 60 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>18 and ≤60 years * Persistent or intermittent allergic rhinitis complaints, confirmed by SPT and/of immunocap for the specific IgEs. OR suspected local allergic rhinitis * Patients who start with AIT treatment * The patient must be motivated and willing to come to all visits * The patient must be able to understand and sign the informed consent Exclusion Criteria: * Uncontrolled asthma * Conditions affecting the functioning of the immune system (eg: immune deficiencies, malignancies, autoimmune diseases) * Use of β-blockers, immunosuppressants or ACE inhibitors * Hypersensitivity to aluminum hydroxide and/or hypersensitivity to any of the excipients in AIT * Anaphylaxis after allergen challenge in the past * Acute rhinosinusitis in the last 12 weeks * Recent surgery on the nose and/or paranasal sinuses in the last 12 weeks * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Local allergic rhinitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic rhinitis perennial allergic rhinitis seasonal allergic rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Local allergic rhinitis Perennial allergic rhinitis Seasonal allergic rhinitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AZ Sint-Jan

    NOT_YET_RECRUITING

    Bruges, 8000, Belgium

  • UZ Leuven

    RECRUITING

    Leuven, Vlaam Brabant, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.